Clinical Data Viridian reports positive results from elegrobart phase 3 trial PharmaTimesCompany says treatment shows strong efficacy and convenient dosing profileClinical DataRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Company says treatment shows strong efficacy and convenient dosing profile Clinical DataRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2DNext: FDA approves new high dose Spinraza regimen for SMA Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
